• AI Technology Group’s merger agreement with AVM Biotechnology and Biomed 360 was amended on June 4, 2026 to extend the timeline.
• The closing date was pushed back to Dec. 31, 2026 from July 26, 2026, with flexibility for a mutually agreed date.
• Funding terms were revised, confirming $1 million of loans funded by Aug. 1, 2025, convertible at $1 per share at the effective time.
• The amendment also confirms $1.125 million of additional loans convertible at $2.5 per share, with further tranche funding scheduled through Nov. 15, 2026.
• The deal contemplates at least $50 million of gross proceeds by closing tied to a senior US listing, targeted by Dec. 31, 2026, extendable to March 31, 2027.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. AI Technology Group Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001477932-26-003844), on June 12, 2026, and is solely responsible for the information contained therein.